# TremelImumab aNd Durvalumab For the Non-operatIve Management (NOM) of MSI-high Resectable GC/GEJC.

> **NCT04817826** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Gruppo Oncologico del Nord-Ovest** · enrollment: 31 (estimated)

## Conditions studied

- Gastric Cancer
- Microsatellite Instability

## Interventions

- **DRUG:** Durvalumab
- **DRUG:** Tremelimumab

## Key facts

- **NCT ID:** NCT04817826
- **Lead sponsor:** Gruppo Oncologico del Nord-Ovest
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-04-01
- **Primary completion:** 2025-04-30
- **Final completion:** 2026-04-30
- **Target enrollment:** 31 (ESTIMATED)
- **Last updated:** 2025-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04817826

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04817826, "TremelImumab aNd Durvalumab For the Non-operatIve Management (NOM) of MSI-high Resectable GC/GEJC.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04817826. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*